ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Maximal radial distance for predicting extraprostatic extension of prostate cancer: a histopathological-radiological study.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimal MRI sequence for predicting extraprostatic extension in prostate cancer: comparison of LCC and MaxRADD measurements.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThere is a lack of a reliable parameter for accurate prediction of extraprostatic extension (EPE) of prostate cancer on MRI. We introduce a new parameter for predicting EPE on MRI: the maximal radial distance (maxRADD). It corresponds to the largest diameter of a prostate cancer focus (PCF) perpendicular to the contact with the prostate pseudocapsule. We compared accuracy and reliability of maxRADD with the previously proposed maximal capsular contact length (maxCCL). MATERIALS AND
methodsIn a single-centre study, we retrospectively included all consecutive patients undergoing prostate MRI between October 2018 and December 2020, followed by radical prostatectomy. One uropathologist and four radiologists determined maxRADD and maxCCL for each PCF. Accuracy in predicting EPE was assessed using the area under the curve (AUC), with optimal sensitivity/specificity cutoffs determined by the Youden J index using the histopathological findings as the gold standard. Correlations between histopathological and MRI values of maxRADD and maxCCL were analyzed using the Pearson correlation coefficient (r). Inter-/intra-reader agreements were evaluated using intraclass correlation coefficients (ICC).
resultsA total of 79 men (mean age ± standard deviation, 65 ± 6 years) were evaluated. Twenty-six (32.9%) patients had prostate cancer with EPE. On histopathology, there was no significant difference in the accuracy of predicting EPE between maxRADD and maxCCL (AUC, 0.92 vs. 0.91, p = 0.28). The optimal cutoffs were ≥ 10.7 mm (sensitivity: 70%; specificity: 90%) for maxRADD and ≥ 12.8 mm (sensitivity: 90%; specificity: 70%) for maxCCL. Pearson correlation showed a strong correlation for maxRADD values determined on MRI with their histopathological counterparts (all r ≥ 0.7) for all readers. On MRI, inter-/intra-reader agreements were good for both parameters but significantly higher for maxRADD than for maxCCL (ICC, 0.87 vs. 0.80, p < 0.001 and 0.90 vs. 0.88, p < 0.001, respectively).
conclusionMaxRADD permits assessing EPE with good accuracy and shows higher reliability compared with maxCCL. Reliable preoperative prediction of EPE improves treatment planning, potentially reducing positive surgical margins and improving outcomes for patients with prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.